Vor Biopharma Stock Annual Yield

VOR Stock

USD 0.82 0.05 5.75%

Vor Biopharma fundamentals help investors to digest information that contributes to Vor Biopharma's financial success or failures. It also enables traders to predict the movement of Vor Stock. The fundamental analysis module provides a way to measure Vor Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vor Biopharma stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vor Biopharma Company Annual Yield Analysis

Vor Biopharma's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

Vor Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for Vor Biopharma is extremely important. It helps to project a fair market value of Vor Stock properly, considering its historical fundamentals such as Annual Yield. Since Vor Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vor Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vor Biopharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Property Plant Equipment	Common Stock	Capital Surpluse
Total Assets		1.0	0.9	0.82	-0.49	-0.86	0.74	0.92	0.95	-0.34	0.99	-0.04	0.99	0.24	0.72	0.92	0.78
Total Stockholder Equity	1.0		0.89	0.81	-0.54	-0.83	0.74	0.89	0.96	-0.33	1.0	-0.06	1.0	0.24	0.69	0.9	0.74
Net Tangible Assets	0.9	0.89		0.69	-0.25	-0.94	0.51	0.85	0.91	-0.62	0.89	-0.3	0.88	0.33	0.55	0.95	0.86
Current Deferred Revenue	0.82	0.81	0.69		-0.46	-0.76	0.85	0.79	0.66	-0.34	0.8	0.35	0.8	-0.31	0.82	0.75	0.66
Net Debt	-0.49	-0.54	-0.25	-0.46		0.1	-0.59	-0.21	-0.45	-0.15	-0.56	-0.22	-0.57	0.23	-0.31	-0.15	0.12
Retained Earnings	-0.86	-0.83	-0.94	-0.76	0.1		-0.57	-0.92	-0.79	0.6	-0.82	0.09	-0.81	-0.16	-0.71	-0.96	-0.92
Accounts Payable	0.74	0.74	0.51	0.85	-0.59	-0.57		0.68	0.51	-0.28	0.73	0.61	0.73	-0.27	0.89	0.53	0.42
Total Liab	0.92	0.89	0.85	0.79	-0.21	-0.92	0.68		0.81	-0.39	0.88	0.07	0.86	0.2	0.84	0.95	0.91
Net Invested Capital	0.95	0.96	0.91	0.66	-0.45	-0.79	0.51	0.81		-0.29	0.96	-0.34	0.96	0.44	0.47	0.89	0.73
Short Long Term Debt	-0.34	-0.33	-0.62	-0.34	-0.15	0.6	-0.28	-0.39	-0.29		-0.32	0.11	-0.31	-0.09	-0.32	-0.49	-0.57
Total Current Assets	0.99	1.0	0.89	0.8	-0.56	-0.82	0.73	0.88	0.96	-0.32		-0.07	1.0	0.25	0.68	0.89	0.72
Capital Stock	-0.04	-0.06	-0.3	0.35	-0.22	0.09	0.61	0.07	-0.34	0.11	-0.07		-0.07	-0.71	0.59	-0.2	-0.17
Net Working Capital	0.99	1.0	0.88	0.8	-0.57	-0.81	0.73	0.86	0.96	-0.31	1.0	-0.07		0.24	0.67	0.88	0.7
Short Term Debt	0.24	0.24	0.33	-0.31	0.23	-0.16	-0.27	0.2	0.44	-0.09	0.25	-0.71	0.24		-0.21	0.31	0.31
Property Plant Equipment	0.72	0.69	0.55	0.82	-0.31	-0.71	0.89	0.84	0.47	-0.32	0.68	0.59	0.67	-0.21		0.65	0.63
Common Stock	0.92	0.9	0.95	0.75	-0.15	-0.96	0.53	0.95	0.89	-0.49	0.89	-0.2	0.88	0.31	0.65		0.95
Capital Surpluse	0.78	0.74	0.86	0.66	0.12	-0.92	0.42	0.91	0.73	-0.57	0.72	-0.17	0.7	0.31	0.63	0.95

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict Vor Biopharma

In accordance with the recently published financial statements, Vor Biopharma has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Price Transformation Now

Price Transformation

Use Price Transformation models to analyze the depth of different equity instruments across global markets

All Next

Launch Module

Vor Fundamentals

	Return On Equity	-0.91
	Return On Asset	-0.44
	Current Valuation	78.66 M
	Shares Outstanding	124.78 M
	Shares Owned By Insiders	32.03 %
	Shares Owned By Institutions	49.53 %
	Number Of Shares Shorted	1.44 M
	Price To Book	1.49 X
	EBITDA	(114.37 M)
	Net Income	(117.86 M)
	Cash And Equivalents	151.09 M
	Cash Per Share	3.97 X
	Total Debt	35.66 M
	Debt To Equity	0.24 %
	Current Ratio	12.95 X
	Book Value Per Share	1.06 X
	Cash Flow From Operations	(100.29 M)
	Short Ratio	3.72 X
	Earnings Per Share	(1.64) X
	Target Price	11.79
	Number Of Employees	168
	Beta	-0.4
	Market Capitalization	108.81 M
	Total Asset	198.13 M
	Retained Earnings	(340.08 M)
	Working Capital	125.23 M
	Net Asset	198.13 M

About Vor Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC